Mesenchymal Stem Cells: A Friend or Foe in Immune-Mediated Diseases

Stem Cell Reviews and Reports

Volumn 11, Issue 2, 2015, Pages 280-287

  Gazdic, Marina ^a   Volarevic, Vladislav ^a   Arsenijevic, Nebojsa ^a   Stojkovic, Miodrag ^a,b  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

^b Spebo Medical ^*  (Serbia)

Author keywords

Autoimmunity; Immunosuppression; Inflammation; Mesenchymal stem cells; Therapy

Indexed keywords

AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; NATURAL KILLER CELL; TH1 CELL;

AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TH1 CELLS;

EID: 84940008537     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-014-9583-3     Document Type: Article

References (75)

1. Friedenstein, A. J., Deriglasova, U. F., Kulagina, N. N., et al. (1974). Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Experimental Hematology, 2(2), 83–92.
2. Pittenger, M. F., Mackay, A. M., Beck, S. C., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143–147.
3. Gebler, A., Zabel, O., & Seliger, B. (2012). The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine, 18(2), 128–134.
4. Volarevic, V., Al-Qahtani, A., Arsenijevic, N., et al. (2010). Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity, 43(4), 255–263.
5. Battula, V. L., Evans, K. W., Hollier, B. G., et al. (2010). Epithelial- mesenchymal transitionderived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells, 28(8), 1435–1445.
6. Takashima, Y., Era, T., Nakao, K., et al. (2007). Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell, 129(7), 1377–1388.
7. Crisan, M., Yap, S., Casteilla, L., et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 3(3), 301–313.
8. Dominici, M., Le Blanc, K., Mueller, I., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy, 8(4), 315–317.
9. Volarevic, V., Ljujic, B., Stojkovic, P., Lukic, A., Arsenijevic, N., & Stojkovic, M. (2011). Human stem cell research and regenerative medicine–present and future. British Medical Bulletin, 99, 155–168.
10. Volarevic, V., Erceg, S., Bhattacharya, S. S., Stojkovic, P., Horner, P., & Stojkovic, M. (2013). Stem cell based therapy for spinal cord injury. Cell Transplantation, 22(8), 1309–1323.
11. Li, W., Ren, G., Huang, Y., et al. (2012). Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death and Differentiation, 19(9), 1505–1513.
12. Duffy, M. M., Ritter, T., Ceredig, R., & Griffin, M. D. (2011). Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Research and Therapy, 2(4), 34.
13. Keating, A. (2008). How do mesenchymal stromal sells suppress T cells? Cell Stem Cell, 2(2), 106–108.
14. Nauta, A. J., & Fibbe, E. W. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood, 110(10), 3499–3506.
15. Ren, G., Su, J., Zhang, L., et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells, 27(8), 1954–1962.
16. Sato, K., Azaki, K., Oh, I., et al. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109(1), 228–234.
17. Bernardo, M. E., & Fibbe, W. E. (2013). Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell, 13(4), 392–402.
18. Meisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103(12), 4619–4621.
19. Glennie, S., Soeiro, I., Dyson, P. J., Lam, E. W., & Dazzi, F. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 105(7), 2821–2827.
20. Di Nicola, M., Carlo-Stella, C., Magni, M., et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99(10), 3838–3843.
21. Nasef, A., Chapel, A., Mazurier, C., et al. (2007). Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expression, 13(4–5), 217–226.
22. Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4), 1815–1822.
23. Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C., & Noël, D. (2010). Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Research & Therapy, 1(1), 2.
24. Chabannes, D., Hill, M., Merieau, E., et al. (2007). A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood, 110(10), 3691–3694.
25. Pae, H., Oh, G. S., Choi, B. M., et al. (2004). Carbon monoxide produced by Heme oxygenase-1 suppresses T cell proliferation by inhibition of IL2 production. Journal of Immunology, 172(8), 4744–4751.
26. Bright, J. J., Kerr, L. D., & Sriram, S. (1997). TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes. Journal of Immunology, 159(1), 175–83.
27. Kalinski, P. (2012). Regulation of immune responses by prostaglandin E2. Journal of Immunology, 188(1), 21–28.
28. Rasmusson, I., Ringden, O., Sundberg, B., & Le Blanc, K. (2005). Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Experimental Cell Research, 305(1), 33–41.
29. Nasef, A., Mazurier, C., Bouchet, S., et al. (2008). Leukemia inhibitory factor: role in human mesenchymal stem cells mediated immunosuppression. Cellular Immunology, 253(1–2), 16–22.
30. Lepelletier, Y., Lecourt, S., Renand, A., et al. (2010). Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells and Development, 19(7), 1075–1079.
31. Sioud, M., Mobergslien, A., Boudabous, A., & Floisand, Y. (2010). Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scandinavian Journal of Immunology, 71(4), 267–274.
32. Sivanathan, K. N., Gronthos, S., Rojas-Canales, D., Thierry, B., & Coates, P. T. (2014). Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Reviews and Reports, 10(3), 351–375.
33. Bassi, Ê. J., de Almeida, D. C., Moraes-Vieira, P. M., & Câmara, N. O. (2012). Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells. Stem Cell Reviews and Reports, 8(2), 329–342.
34. Duffy, M. M., Pindjakova, J., Hanley, S. A., et al. (2011). Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. European Journal of Immunology, 41(10), 2840–2851.
35. Nauta, A., Kruisselbrink, A., Lurvink, E., Willemze, R., & Fibbe, W. (2006). Mesenchymal stem cells inhibit generation and function of both CD34+−derived and monocyte-derived dendritic cells. Journal of Immunology, 177(4), 2080–2087.
36. Ramasamy, R., Fazekasova, H., Lam, E., Soeiro, I., Lombardi, G., & Dazzi, F. (2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation, 83(1), 71–76.
37. Zhang, W., Ge, W., Li, C., et al. (2004). Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells and Development, 13(3), 263–271.
38. Jiang, X. X., Zhang, Y., Liu, B., et al. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105(10), 4120–4126.
39. Djouad, F., Charbonnier, L. M., Bouffi, C., et al. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells, 25(8), 2025–2032.
40. Spaggiari, G. M., Abdelrazik, H., Becchetti, F., & Moretta, L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 113(26), 6576–6583.
41. Beyth, S., Borovsky, Z., Mevorach, D., et al. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood, 105(5), 2214–2219.
42. Liu, W. H., Liu, J. J., Wu, J., et al. (2013). Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One, 8(1), e55487.
43. Ghannam, S., Pène, J., Moquet-Torcy, G., Jorgensen, C., & Yssel, H. (2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Journal of Immunology, 185(1), 302–312.
44. Del Papa, B., Sportoletti, P., Cecchini, D., et al. (2013). Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction. European Journal of Immunology, 43(1), 182–187.
45. Maccario, R., Podesta, M., Moretta, A., et al. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 90(4), 516–525.
46. Selmani, Z., Naji, A., Zidi, I., et al. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+regulatory T cells. Stem Cells, 26(1), 212–222.
47. English, K., Ryan, J. M., Tobin, L., Murphy, M. J., Barry, F. P., & Mahon, B. P. (2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clinical and Experimental Immunology, 156(1), 149–160.
48. Rasmusson, I., Uhlin, M., Le Blanc, K., & Levitsky, V. (2007). Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. Journal of Leukocyte Biology, 82(4), 887–893.
49. Li, M., Sun, X., Kuang, X., Liao, Y., Li, H., & Luo, D. (2014). Mesenchymal stem cells suppress CD8(+) T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-β. Clinical and Experimental Immunology, 178(3), 516–524.
50. Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24(1), 74–85.
51. Krampera, M., Cosmi, L., Angeli, R., et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24(2), 386–398.
52. Spaggiari, G. M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 111(3), 1327–1333.
53. Rasmusson, I., Ringden, O., Sundberg, B., & Le Blanc, K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 76(8), 1208–1213.
54. Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., & Moretta, L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107(4), 1484–1490.
55. Prigione, I., Benvenuto, F., Bocca, P., Battistini, L., Uccelli, A., & Pistoia, V. (2009). Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells, 27(3), 693–702.
56. Prockop, D. J. (2013). Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells, 31(10), 2042–2046.
57. Eggenhofer, E., & Hoogduijn, M. J. (2012). Mesenchymal stem cell-educated macrophages. Transplantation Research, 1(1), 12.
58. Melief, S., Schrama, E., Brugman, M., et al. (2013). Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells, 31(9), 1980–1991.
59. Németh, K., Leelahavanichkul, A., Yuen, P. S., et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine, 15(1), 42–49.
60. Choi, H., Lee, R. H., Bazhanov, N., Oh, J. Y., & Prockop, D. J. (2011). Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis bydecreasing TLR2/NF-κB signaling in resident macrophages. Blood, 118(2), 330–338.
61. Melief, S., Geutskens, S., Fibbe, W., & Roelofs, H. (2013). Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica, 98(6), 888–895.
62. François, M., Romieu-Mourez, R., Li, M., & Galipeau, J. (2012). Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Molecular Therapy The Journal of the American Society of Gene Therapy, 20(1), 187–195.
63. Tabera, S., Perez-Simon, J. A., Diez-Campelo, M., et al. (2008). The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica, 93(9), 1301–1309.
64. Corcione, A., Benvenuto, F., Ferretti, E., et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood, 107(1), 367–372.
65. Rafei, M., Hsieh, J., Fortier, S., et al. (2008). Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood, 112(13), 4991–4998.
66. Dazzi, F., & Krampera, M. (2011). Mesenchymal stem cells and autoimmune diseases. Best Practice & Research Clinical Haematology, 24(1), 49–57.
67. Ren, G., Zhang, L., Zhao, X., et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2(2), 141–150.
68. Waterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010). A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One, 5(4), e10088.
69. Raffaghello, L., Bianchi, G., Bertolotto, M., et al. (2008). Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells, 26(1), 151–162.
70. Cassatella, M. A., Mosna, F., Micheletti, A., et al. (2011). Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells, 29(6), 1001–1011.
71. Brandau, S., Jakob, M., Hemeda, H., et al. (2010). Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge. Journal of Leukocyte Biology, 88(5), 1005–1015.
72. Hall, S. R., Tsoyi, K., Ith, B., et al. (2013). Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils. Stem Cells, 31(2), 397–407.
73. Traggiai, E., Volpi, S., Schena, F., et al. (2008). Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells, 26(2), 562–569.
74. Griffin, M., Elliman, S. J., Cahill, E., English, K., Ceredig, R., & Ritter, T. (2013). Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? Stem Cells, 31(10), 2033–2041.
75. Rasmusson, I., Le Blanc, K., Sundberg, B., & Ringdén, O. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scandinavian Journal of Immunology, 65(4), 336–343.